|
市場調查報告書
新藥再開發策略
Drug Repositioning Strategies for Refueling the Pipeline
|
本報告已在2011年12月21日停止出版。
製藥企業雖然企圖開發既有藥物在新的適用病症的應用以增加利益，但也有許多企業採取低風險的新藥再開發策略。
專門於醫療產業相關廣泛調查的美國市調公司 Decision Resources Inc. 總公司：Massachusetts State），針對新藥再開發策略進行調查分析，並系統整理調查結果後出版報告書"Drug Repositioning Strategies for Refueling the Pipeline"。
本報告書內容包括：體內技術、體外技術、體?細胞技術、電腦模擬技術概要、新藥再開發方針及其策略等。內容綱要摘記如下：
實施概要
介紹
體內技術
- 動物實驗對象的即時影像監測
- 斑馬魚疾病模式
- 體內多重分析
體外技術
體內細胞技術
- Bionaut Pharmaceuticals
- CombinatoRx
- Gene Logic
電腦模擬技術
- Archnova
- Inpharmatica
- Off-label.com
- 股份有限公司Sosei
- Gene Logic
治療領域的新藥再開發
- Dynogen
- Jenken Biosciences
- Vicus Therapeutics
- BrainCells
新藥再開發策略
新藥再開發的未來發展預測
表
- 新藥再開發技術
- 有新藥再開發技術及計畫的企業
- 新藥再開發相關合作
圖
- FDA認可的新分子（1997年至2006年）及全球研發費用、PhRMA成員（1997年至2005年）
- 針對新藥再開發的體內及體外技術
- 針對新藥再開發的體內細胞技術
- 針對新藥再開發的電腦模擬技術
Abstract
Introduction:
Drug companies have historically found new indications for their existing
drugs serendipitously. Now, however, to refuel product pipelines and improve
profi t margins, many companies are turning to low-risk strategies such as
drug repositioning. Biotech companies such as Dynogen, BrainCells, Gene Logic,
and Xenogen are developing technology platforms that aid companies in the
development of systematic approaches to this low-risk strategy.
Questions Answered in This Spectrum Report:
- Many new in vivo, ex vivo, in vitro, and in silico drug repositioning
approaches are just now emerging. Which approach is likely to have the
greatest success in fi nding unexpected new indications for drugs?
- The pharmaceutical industry is beginning to adopt technologies based on
metabolomics-the comprehensive analysis of metabolites. Which companies are
pursuing metabolomics as their primary approach to drug repositioning?
- Gene Logic' s Phase R Program covers the up-front costs of drug discovery
for companies with which it partners. Has Gene Logic' s risky strategy been
successful in attracting partners? What other partnering strategies are
repositioning companies actively pursuing?
- CombinatoRx has developed a high-throughput screening system to evaluate
pairs of known compounds for specifi c diseases. What successes has
CombinatoRx had in identifying new combinations of known drugs to be used in
specifi c diseases?
- An essential part of the business strategy for repositioning compounds is
ensuring a strong patent estate. What repositioned drugs are most likely to
achieve the strongest patent protection?
Scope:
- In vivo technologies: real-time imaging, zebra fi sh modeling, and
multiplexing.
- Ex vivo technologies: kinetic markers and metabolomics.
- In vitro cell-based technologies: genetically engineered cell lines and
high-throughput screening.
- In silico technologies: computer simulations and database analyses.
- Repositioning approaches: technology platforms enabling a systematic
approach to fi nding new uses for drugs; use of animal models, cell-based
assays, computer simulations, and database analyses; pathway-based approaches;
the "hypothesis-free" approach.
- Strategies in drug repositioning: trends in repositioning efforts;
intellectual property strategies; business models; licensing and collaborative
partnerships.
- Outlook: Big Pharma' s interest in drug repositioning; the promise of in
vivo models; hopes for a powerful technology toolbox; repositioning of branded
versus patented drugs.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- In Vivo Technologies
- Real-Time Imaging in Animal Models
- Zebra Fish Disease Models
- In Vivo Multiplexing
- Ex Vivo Technologies
- Kinetic Markers
- Metabolomics
- In Vitro Cell-Based Technologies
- Bionaut Pharmaceuticals
- CombinatoRx
- Gene Logic
- In Silico Technologies
- Arachnova
- Inpharmatica
- Off-label.com
- Sosei
- Gene Logic
- Repositioning Within a Therapeutic Area
- Dynogen
- Jenken Biosciences
- Vicus Therapeutics
- BrainCells
- Strategies in Drug Repositioning
- Technology Strategies
- Intellectual Property Strategies
- Business Models
- Outlook for Drug Repositioning
Tables
- 1. Select Technologies for Drug Repositioning
- 2. Select Companies with Drug Repositioning Technologies or Programs
- 3. Select Collaborations in Drug Repositioning
Figures
- 1. Number of FDA-Approved New Molecular Entities (1997-2006) and Total
Global R&D Spending, PhRMA Members (1997-2005)
- 2. In Vivo and Ex Vivo Technologies for Drug Repositioning
- 3. In Vitro, Cell-Based Assays for Drug Repositioning
- 4. In Silico Technologies for Drug Repositioning
|
